Optimal haloperidol dosage in first-episode psychosis

Canadian Journal of Psychiatry

Volumn 44, Issue 2, 1999, Pages 164-167

  Zhang Wong, J ^a,c   Zipursky, R B ^b   Beiser, M ^b   Bean, G ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Clarke Division   (Canada)

Author keywords

First episode psychosis; Haloperidol optimal treatment; Haloperidol plasma level

Indexed keywords

HALOPERIDOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; PSYCHOSIS; SYMPTOM; TREATMENT OUTCOME;

EID: 0032913965     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674379904400207     Document Type: Article

References (17)

1. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis. Arch Gen Psychiatry 1988;45:79-91.
2. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. Arch Gen Psychiatry 1991;48:739-45.
3. Spitzer L, Janet BW, William DSW. Structured Clinical Interview for DSM-III-R (SCID). Washington (DC):American Psychiatric Press; 1990.
4. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (SCI-PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
5. Leckman JF, Scholomskas D, Thompson WD, Belanger A, Weissman MM. Best estimates of lifetime psychiatric diagnosis: a methodological study. Arch Gen Psychiatry 1982;39:879-83.
6. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Arch Gen Psychiatry 1991;48:764-70.
7. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, and others. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
8. Chouinard G, Ross-Chouinard A, Annable L. Extrapyramidal Symptom Rating Scale (ESRS). Can J Neurol Sci 1980;7:233-43.
9. Lin KM, Poland RE, Nuccio I, Matsuda K, Hathuc N, Su TP, and others. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am J Psychiatry 1989;146:1307-11.
10. Stone CK, Garver DL, Griffith J, Hirschowitz J, Bennett J. Further evidence of a dose-response threshold for haloperidol in psychosis. Am J Psychiatry 1995;152:1210-2.
11. Haase HJ. Extrapyramidal modification of fine movements: a "conditio sine qua non" of the fundamental therapeutic action of neuroleptic drugs. In: Bordeleau JM, editor. Systeme extrapyramidal et neuroleptiques. Montreal (QC): Editions Psychiatriques; 1961. p 329-53.
12. McEvoy JP. The neuroleptic threshold as a marker of minimum effective neuroleptic dose. Compr Psychiatry 1986;27:327-35.
13. Davis JM, Garver DL. Neuroleptics: clinical use in psychiatry. In: Iversen LL, editor. Handbook of psychopharmacology. Volume 10. Neuroleptics and schizophrenia. New York: Plenum; 1978.
14. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996;153:948-50.
15. 2-dopamine receptor occupancy in relation to antipsychotic drug effects - a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-35.
16. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-44.
17. Freudenreich O, McEvoy JP. How much Haldol does Larry really need. J Clin Psychiatry 1995;56:331-2.